We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 37

Synageva announces $25 million for rare disease product development

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • April 7 2011

Synageva BioPharma Corp. has announced an additional $25 million in private equity financing to support therapeutic product development

NASDAQ Biotechnology Index surpasses all-time high in 1Q13

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 16 2013

The NASDAQ Biotechnology Index reportedly rose in the first quarter of 2013 (1Q13) above levels last seen during the 2000 genomics bubble peakthe

Corporate venture funding for funding surges

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • August 7 2014

Silicon Valley Bank (SVB) has issued a report that explores health-care and biotech investments and exits based on 2013 data and concludes, "Large

Venture capitalists are returning to life-sciences investing

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • October 3 2012

Reuters reports that a number of global venture firms have renewed their interest in the life sciences and health-care sectors, motivated by big acquisitions, U.S. laws speeding up certain drug approval processes and new products that have broadened the life-sciences definition

Quebec establishes new venture capital fund to invest in biotech research

  • Shook Hardy & Bacon LLP
  • -
  • Canada
  • -
  • February 24 2011

Quebec's Charest administration has reportedly launched the third of three new venture capital funds to provide more than $41 million for investment in biotechnology research

Fewer small biotech companies go public

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • March 10 2011

Smaller biotechnology companies maneuvering through drug-development regulations are reportedly focusing their efforts on licensing products in development or selling their businesses to large pharmaceutical companies rather than pursuing an initial public offering (IPO

Agilent Technologies acquires BIOCIUS Life Sciences

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • March 10 2011

California-based Agilent Technologies has announced the acquisition of BIOCIUS Life Sciences, a Massachusetts-based company that developed a spectrometry device, enabling "researchers to gain a fuller understanding of a drug's biochemical properties, including potential liabilities in drug interactions

Viropharma to acquire Swedish pharma in deal worth up to $164.6 million

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • November 3 2011

Pennsylvania-based ViroPharma Inc. has reportedly signed a deal to acquire Swedish company DuoCort Pharma AB to expand its orphan disease commercial product pipeline

Biotech IPO market, booming or bubbling?

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • October 17 2013

Speakers at a recent Biotechnology Industry Organization (BIO) Investor Forum in San Francisco reportedly claimed that this year's successes for

Indian officials to scrutinize pharmaceutical M&As

  • Shook Hardy & Bacon LLP
  • -
  • India
  • -
  • October 20 2011

Indian ministry officials have apparently decided that foreign companies may continue to invest in new pharmaceutical industry projects but that foreign proposals for mergers and acquisitions in this sector will have to undergo enhanced scrutiny